Novel combination approaches in various solid tumors
The anti-angiogenic multikinase inhibitor lenvatinib has been shown to exert immunomodulatory effects that enhance the anti-tumor activity of anti-PD-1 antibodies. In the early-phase setting, lenvatinib plus pembrolizumab induced partial responses in patients with different tumor types.